Back to top

TScan’s TSC-101 Trial: A New Cell Therapy Bet in Transplant Oncology

Tscan Therapeutics, Inc. ($TCRX) announced an update on their ongoing clinical study. The Phase 3 study titled “A Phase 1/3 Study Evaluating the Ef...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

TScan Therapeutics, Inc. (TCRX)